Abstract
Background and Objectives ABCA1 has been associated with Alzheimer’s Disease (AD) via large-scale genetic studies, but the mechanisms by which it impacts disease risk are unknown. ABCA1 catalyzes apolipoprotein lipidation in the central nervous system and is known to interact molecularly with ApoE. We explored whether variants altering ABCA1 activity depend on the presence of different APOE isoforms to modify AD risk.
Methods We meta-analyzed European- and African-ancestry whole-genome and whole-exome sequencing datasets from the Alzheimer’s Disease Sequencing Project and UK Biobank. We used Cox hazards regression to assess the impact of rare (MAF < 1%) predicted damaging (loss-of-function, or missense with a REVEL score ≥ 0.75) variants in ABCA1 on AD risk in APOE subgroups and performed APOE interaction analyses considering all APOE genotypes. We then leveraged plasma HDL levels, a phenotype known to be impacted by ABCA1 variants, as a measure of ABCA1 activity and examined whether cumulative effects on HDL levels by ABCA1 missense variants predict AD risk.
Results Rare damaging (LOF + REVEL ≥ 75) variants on ABCA1 increased AD risk in APOE ε2/ε3 and ε3/ε3 but not ε3/ε4 or ε4/ε4 cohorts. Interaction analyses indicated that damaging ABCA1 variants increase AD risk considering all APOE isoforms (hazard ratio [HR] = 1.48; 95% confidence interval [CI] = 1.22, 1.79; p = 5.80E-05) and interact with both APOE ε2 (HR = 1.99; 95% CI = 1.30, 3.05; p = 0.002) and ε4 (HR = 0.76; 95% CI = 0.61, 0.95; p = 0.014). Predicted ABCA1 activity based on a weighted sum of HDL-associated ABCA1 missense variants was protective against AD (HR = 0.10; 95% CI = 0.04, 0.27; p = 2.83E-06) and interacted with APOE ε4 to counteract this protective effect (HR = 11.66; 95% CI = 3.81, 35.66; p = 1.67E-05), while there was no significant interaction with ε2.
Conclusions ABCA1 activity is protective against AD risk in APOE ε4 non-carriers. Distinct interactions between ABCA1 and the main APOE isoforms suggest the proteins may work together to affect AD risk and motivate the development and testing of ABCA1 therapeutics in specific APOE subpopulations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by NIH grants R35AG072290 and P30AG066515, as well as a Wu Tsai Neurosciences Institute Seed Grants Program grant, accessible at https://neuroscience.stanford.edu/our-science/funded-projects/structural-and-mechanistic-analysis-protein-protein-interface-between-abca1-and-apoe-potential-therapeutic-target-alzheimers-disease. For funding sources related to ADSP and UKB datasets, see Supplementary Acknowledgements.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Stanford University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.